Patient P-01307

Synthetic patientNBL-101 · Day 110 · 65–74 · F · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Favorable

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

84%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −25% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 50 GI-04 recommended — GI Support Protocol GI-04
Day 51 Patient accepted — Started GI-04 in the companion
Day 59 GI symptom burden −34% vs expected — GI Support Protocol GI-04
Day 65 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 65 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 65.

Primary contributors, last 14 days

GI instability+18
Inflammatory activity+11
Nutritional resilience-6
Treatment adherence+5
Toxicity+2

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −25%
GI Support Protocol GI-04Day 50
Result: symptom burden −34%

LIFE OS recommendation

Monitoring Escalation ME-01

92%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Drug metabolism and exposure ↑75
- DNACYP2D6 poor metabolizer → higher exposure
- DNADPYD *2A → slower clearance
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 54 and rising
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 55
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 2.8 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 58 ms
Sleep: 7.4 h
Steps: 4,857
Resting HR: 65 bpm

Daily log: GI score 54, nutritional resilience 44, adherence 56.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01505	56%	S14	NP-02	improved	41
P-01570	55%	S14	SC-12	improved	46
P-01603	53%	S14	GI-04	improved	40
P-01616	53%	S14	GI-04	improved	39
P-01356	51%	S14	GI-04	improved	42
P-01436	51%	S14	GI-04	improved	38
P-01486	51%	S18	GI-04	improved	47
P-01556	51%	S14	GI-04	improved	44
P-01713	51%	S04	GI-04	improved	46
P-01781	51%	S14	NP-02	improved	45
P-01473	50%	S14	GI-04	improved	51
P-01539	50%	S14	GI-04	improved	43